New drug targets Hard-to-Treat cancers in early trial
Disease control
Not yet recruiting
This early-phase study tests a new drug called CRPA1A2 in people with advanced solid tumors (lung, esophagus, head and neck, or liver cancer) that have not responded to standard treatments. The drug is designed to help the body's immune cells attack cancer cells that have a speci…
Phase: PHASE1 • Sponsor: Corregene Biotechnology Co., Ltd • Aim: Disease control
Last updated May 26, 2026 09:35 UTC